Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
JAGX Quote, Financials, Valuation and Earnings
Last price:
$0.40
Seasonality move
:
-13.09%
Day range:
$0.37 - $0.41
52-week range:
$0.31 - $15.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
0.16x
Volume:
197.1K
Avg. volume:
511K
1-year change:
-91.43%
Market cap:
$501.4K
Revenue:
$11.7M
EPS (TTM):
-$33.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$4.2M | -$1.49 | 20.18% | -92.94% | $7.50 |
|
ICU
Seastar Medical Holding Corp.
|
$437.5K | -- | 43.94% | -- | $9.00 |
|
JUNS
Jupiter Neurosciences
|
-- | -- | -- | -- | -- |
|
MTVA
MetaVia, Inc.
|
-- | -$0.65 | -- | -69.19% | $19.33 |
|
PHIO
Phio Pharmaceuticals Corp.
|
-- | -$0.24 | -- | -42.78% | $14.00 |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$4.9M | -$2.55 | 159.37% | -10.19% | $54.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$0.40 | $7.50 | $501.4K | -- | $0.00 | 0% | 0.14x |
|
ICU
Seastar Medical Holding Corp.
|
$4.31 | $9.00 | $20.7M | -- | $0.00 | 0% | 16.85x |
|
JUNS
Jupiter Neurosciences
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MTVA
MetaVia, Inc.
|
$1.26 | $19.33 | $32M | -- | $0.00 | 0% | -- |
|
PHIO
Phio Pharmaceuticals Corp.
|
$1.28 | $14.00 | $14.6M | -- | $0.00 | 0% | -- |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$13.90 | $54.33 | $103.9M | -- | $0.00 | 0% | 9.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
85.01% | -3.752 | 766.14% | 0.14x |
|
ICU
Seastar Medical Holding Corp.
|
4.8% | -4.283 | 6.07% | 3.27x |
|
JUNS
Jupiter Neurosciences
|
-- | 0.000 | -- | -- |
|
MTVA
MetaVia, Inc.
|
3.79% | 3.907 | 0.1% | 1.82x |
|
PHIO
Phio Pharmaceuticals Corp.
|
-- | 0.120 | -- | 15.69x |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
0.53% | 5.676 | 1.14% | 7.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAGX
Jaguar Health, Inc.
|
$2M | -$7.2M | -97.4% | -524.57% | -234.77% | -$4.7M |
|
ICU
Seastar Medical Holding Corp.
|
$408K | -$3M | -242.37% | -257.38% | -718.1% | -$4.1M |
|
JUNS
Jupiter Neurosciences
|
-- | -- | -- | -- | -- | -- |
|
MTVA
MetaVia, Inc.
|
-$5K | -$2M | -189.44% | -193.06% | -- | -$4.9M |
|
PHIO
Phio Pharmaceuticals Corp.
|
-$1K | -$2.5M | -76.33% | -76.33% | -- | -$2.1M |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
$3.8M | -$48.3M | -63.59% | -64.31% | -895.84% | -$42.4M |
Jaguar Health, Inc. vs. Competitors
-
Which has Higher Returns JAGX or ICU?
Seastar Medical Holding Corp. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -691.43%. Jaguar Health, Inc.'s return on equity of -524.57% beat Seastar Medical Holding Corp.'s return on equity of -257.38%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M ICUSeastar Medical Holding Corp.97.14% -$0.80 $10.9M -
What do Analysts Say About JAGX or ICU?
Jaguar Health, Inc. has a consensus price target of $7.50, signalling upside risk potential of 1775%. On the other hand Seastar Medical Holding Corp. has an analysts' consensus of $9.00 which suggests that it could grow by 108.82%. Given that Jaguar Health, Inc. has higher upside potential than Seastar Medical Holding Corp., analysts believe Jaguar Health, Inc. is more attractive than Seastar Medical Holding Corp..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.0 0 0 ICUSeastar Medical Holding Corp.0 0 0 -
Is JAGX or ICU More Risky?
Jaguar Health, Inc. has a beta of 0.274, which suggesting that the stock is 72.61% less volatile than S&P 500. In comparison Seastar Medical Holding Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JAGX or ICU?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seastar Medical Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Seastar Medical Holding Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or ICU?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Seastar Medical Holding Corp. quarterly revenues of $420K. Jaguar Health, Inc.'s net income of -$9.6M is lower than Seastar Medical Holding Corp.'s net income of -$2.9M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Seastar Medical Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.14x versus 16.85x for Seastar Medical Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.14x -- $3.1M -$9.6M ICUSeastar Medical Holding Corp.16.85x -- $420K -$2.9M
-
Which has Higher Returns JAGX or JUNS?
Jupiter Neurosciences has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of --. Jaguar Health, Inc.'s return on equity of -524.57% beat Jupiter Neurosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M JUNSJupiter Neurosciences-- -- -- -
What do Analysts Say About JAGX or JUNS?
Jaguar Health, Inc. has a consensus price target of $7.50, signalling upside risk potential of 1775%. On the other hand Jupiter Neurosciences has an analysts' consensus of -- which suggests that it could fall by --. Given that Jaguar Health, Inc. has higher upside potential than Jupiter Neurosciences, analysts believe Jaguar Health, Inc. is more attractive than Jupiter Neurosciences.
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.0 0 0 JUNSJupiter Neurosciences0 0 0 -
Is JAGX or JUNS More Risky?
Jaguar Health, Inc. has a beta of 0.274, which suggesting that the stock is 72.61% less volatile than S&P 500. In comparison Jupiter Neurosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JAGX or JUNS?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jupiter Neurosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Jupiter Neurosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or JUNS?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Jupiter Neurosciences quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is higher than Jupiter Neurosciences's net income of --. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Jupiter Neurosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.14x versus -- for Jupiter Neurosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.14x -- $3.1M -$9.6M JUNSJupiter Neurosciences-- -- -- --
-
Which has Higher Returns JAGX or MTVA?
MetaVia, Inc. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of --. Jaguar Health, Inc.'s return on equity of -524.57% beat MetaVia, Inc.'s return on equity of -193.06%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M MTVAMetaVia, Inc.-- -$0.84 $5.5M -
What do Analysts Say About JAGX or MTVA?
Jaguar Health, Inc. has a consensus price target of $7.50, signalling upside risk potential of 1775%. On the other hand MetaVia, Inc. has an analysts' consensus of $19.33 which suggests that it could grow by 1434.39%. Given that Jaguar Health, Inc. has higher upside potential than MetaVia, Inc., analysts believe Jaguar Health, Inc. is more attractive than MetaVia, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.0 0 0 MTVAMetaVia, Inc.1 0 0 -
Is JAGX or MTVA More Risky?
Jaguar Health, Inc. has a beta of 0.274, which suggesting that the stock is 72.61% less volatile than S&P 500. In comparison MetaVia, Inc. has a beta of 0.347, suggesting its less volatile than the S&P 500 by 65.299%.
-
Which is a Better Dividend Stock JAGX or MTVA?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. MetaVia, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or MTVA?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than MetaVia, Inc. quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is lower than MetaVia, Inc.'s net income of -$1.9M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while MetaVia, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.14x versus -- for MetaVia, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.14x -- $3.1M -$9.6M MTVAMetaVia, Inc.-- -- -- -$1.9M
-
Which has Higher Returns JAGX or PHIO?
Phio Pharmaceuticals Corp. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of --. Jaguar Health, Inc.'s return on equity of -524.57% beat Phio Pharmaceuticals Corp.'s return on equity of -76.33%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M PHIOPhio Pharmaceuticals Corp.-- -$0.20 $20.1M -
What do Analysts Say About JAGX or PHIO?
Jaguar Health, Inc. has a consensus price target of $7.50, signalling upside risk potential of 1775%. On the other hand Phio Pharmaceuticals Corp. has an analysts' consensus of $14.00 which suggests that it could grow by 993.75%. Given that Jaguar Health, Inc. has higher upside potential than Phio Pharmaceuticals Corp., analysts believe Jaguar Health, Inc. is more attractive than Phio Pharmaceuticals Corp..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.0 0 0 PHIOPhio Pharmaceuticals Corp.1 0 0 -
Is JAGX or PHIO More Risky?
Jaguar Health, Inc. has a beta of 0.274, which suggesting that the stock is 72.61% less volatile than S&P 500. In comparison Phio Pharmaceuticals Corp. has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.058%.
-
Which is a Better Dividend Stock JAGX or PHIO?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Phio Pharmaceuticals Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or PHIO?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are larger than Phio Pharmaceuticals Corp. quarterly revenues of --. Jaguar Health, Inc.'s net income of -$9.6M is lower than Phio Pharmaceuticals Corp.'s net income of -$2.4M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Phio Pharmaceuticals Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.14x versus -- for Phio Pharmaceuticals Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.14x -- $3.1M -$9.6M PHIOPhio Pharmaceuticals Corp.-- -- -- -$2.4M
-
Which has Higher Returns JAGX or TNXP?
Tonix Pharmaceuticals Holding Corp. has a net margin of -312.94% compared to Jaguar Health, Inc.'s net margin of -870.32%. Jaguar Health, Inc.'s return on equity of -524.57% beat Tonix Pharmaceuticals Holding Corp.'s return on equity of -64.31%.
Company Gross Margin Earnings Per Share Invested Capital JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M TNXPTonix Pharmaceuticals Holding Corp.71.32% -$3.98 $246.5M -
What do Analysts Say About JAGX or TNXP?
Jaguar Health, Inc. has a consensus price target of $7.50, signalling upside risk potential of 1775%. On the other hand Tonix Pharmaceuticals Holding Corp. has an analysts' consensus of $54.33 which suggests that it could grow by 290.89%. Given that Jaguar Health, Inc. has higher upside potential than Tonix Pharmaceuticals Holding Corp., analysts believe Jaguar Health, Inc. is more attractive than Tonix Pharmaceuticals Holding Corp..
Company Buy Ratings Hold Ratings Sell Ratings JAGXJaguar Health, Inc.0 0 0 TNXPTonix Pharmaceuticals Holding Corp.2 0 0 -
Is JAGX or TNXP More Risky?
Jaguar Health, Inc. has a beta of 0.274, which suggesting that the stock is 72.61% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding Corp. has a beta of 1.753, suggesting its more volatile than the S&P 500 by 75.303%.
-
Which is a Better Dividend Stock JAGX or TNXP?
Jaguar Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health, Inc. pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAGX or TNXP?
Jaguar Health, Inc. quarterly revenues are $3.1M, which are smaller than Tonix Pharmaceuticals Holding Corp. quarterly revenues of $5.4M. Jaguar Health, Inc.'s net income of -$9.6M is higher than Tonix Pharmaceuticals Holding Corp.'s net income of -$46.9M. Notably, Jaguar Health, Inc.'s price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health, Inc. is 0.14x versus 9.15x for Tonix Pharmaceuticals Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAGXJaguar Health, Inc.0.14x -- $3.1M -$9.6M TNXPTonix Pharmaceuticals Holding Corp.9.15x -- $5.4M -$46.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
